Merck KGaA, a leading German company in science and technology, has announced the signing of a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST) to enhance scientific collaboration and advance life sciences research.
This partnership aims to strengthen the research and development ecosystem in South Korea, particularly for industrial applications. Under this agreement, Merck will supply a range of products from its chemistry and biology portfolios to KAIST researchers. Additionally, Merck will provide development opportunities for KAIST researchers to foster innovation and growth.
The collaboration will also involve the establishment of an experience lab in South Korea, further solidifying the cooperative efforts between the two institutions.
Matthias Heinzel, Member of the Executive Board of Merck and CEO of Life Science, commented, "Our collaboration with KAIST marks a significant milestone in accelerating biotechnology advancements, both locally and globally. By advancing research and nurturing the next generation of scientists, we aim to discover new medicines that address the needs of a global population. This is how we impact life and health through science."
In a related development, Merck announced in March a €300 million investment to construct a new bioprocessing production facility in Daejeon, South Korea.
